BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 3 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $133,824 | -45.6% | 18,875 | +22.1% | 0.00% | – |
| Q2 2021 | $246,000 | -5.4% | 15,463 | -55.7% | 0.00% | – |
| Q4 2020 | $260,000 | +58.5% | 34,869 | -25.7% | 0.00% | – |
| Q3 2020 | $164,000 | -73.9% | 46,928 | -64.4% | 0.00% | -100.0% |
| Q2 2020 | $628,000 | +64.4% | 131,772 | -31.8% | 0.00% | 0.0% |
| Q1 2020 | $382,000 | +905.3% | 193,165 | +1660.4% | 0.00% | – |
| Q4 2019 | $38,000 | -52.5% | 10,973 | -13.3% | 0.00% | – |
| Q4 2016 | $80,000 | – | 12,654 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $62,538,000 | 25.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,720,733 | $27,979,000 | 5.53% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 57,000 | $19,282,000 | 4.35% |
| MPM BioImpact LLC | 639,089 | $10,392,000 | 2.79% |
| Parkman Healthcare Partners LLC | 476,978 | $7,756,000 | 2.27% |
| Sarissa Capital Management LP | 1,390,790 | $22,614,000 | 2.14% |
| Ghost Tree Capital, LLC | 350,000 | $5,691,000 | 1.24% |
| Lisanti Capital Growth, LLC | 662,644 | $10,775,000 | 1.21% |
| Baker Brothers Advisors | 12,710,818 | $206,678,000 | 1.19% |
| Tamarack Advisers, LP | 125,000 | $2,033,000 | 0.96% |